Traders Purchase Large Volume of Call Options on Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) saw unusually large options trading on Tuesday. Investors bought 205,487 call options on the company. This is an increase of approximately 19% compared to the average daily volume of 172,606 call options.

Analysts Set New Price Targets

Several brokerages have commented on HIMS. TD Cowen lowered their price objective on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, March 27th. Barclays raised their price objective on Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, March 11th. Canaccord Genuity Group set a $32.00 price objective on Hims & Hers Health in a research report on Tuesday. Morgan Stanley lowered their price objective on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. Finally, Citigroup raised their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research report on Tuesday. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $29.50.

Insiders Place Their Bets

In related news, CFO Oluyemi Okupe sold 19,645 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was sold at an average price of $29.96, for a total value of $588,564.20. Following the completion of the sale, the chief financial officer owned 262,954 shares of the company’s stock, valued at $7,878,101.84. This trade represents a 6.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 97,289 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $2,402,065.41. Following the completion of the sale, the chief operating officer directly owned 407,282 shares of the company’s stock, valued at $10,055,792.58. The trade was a 19.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 204,857 shares of company stock worth $5,285,706. Insiders own 11.76% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after buying an additional 1,407,651 shares during the last quarter. Capital World Investors raised its position in Hims & Hers Health by 1.2% in the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock worth $1,065,399,000 after buying an additional 223,892 shares during the last quarter. Farallon Capital Management LLC raised its position in Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after buying an additional 2,533,271 shares during the last quarter. State Street Corp raised its position in Hims & Hers Health by 1.8% in the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after buying an additional 132,311 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Hims & Hers Health by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after purchasing an additional 608,950 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

HIMS opened at $24.11 on Thursday. The stock has a 50-day moving average price of $23.45 and a 200-day moving average price of $29.11. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.70. The firm has a market cap of $5.50 billion, a PE ratio of -267.87, a P/E/G ratio of 3.31 and a beta of 2.43. Hims & Hers Health has a 1 year low of $13.74 and a 1 year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. During the same period last year, the firm posted $0.20 EPS. Hims & Hers Health’s quarterly revenue was up 3.8% compared to the same quarter last year. Sell-side analysts predict that Hims & Hers Health will post 0.54 earnings per share for the current fiscal year.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Needham raised its price target on Hims & Hers to $35 and reiterated a Buy rating, suggesting some analysts still see meaningful upside after the post-earnings selloff. Benzinga report
• Positive Sentiment: JPMorgan kept an Overweight rating and lowered its target to $33, indicating the stock may have already reset enough to support longer-term growth expectations. JPMorgan price target update
• Positive Sentiment: Bank of America trimmed its target to $30 but maintained a Neutral rating, which implies analysts are still seeing upside from current levels despite the weak quarter. Bank of America price target update
• Neutral Sentiment: Some commentary argues the market may be focusing on the wrong quarter, pointing to stronger subscriber growth and management’s raised revenue outlook as signs the long-term story is intact. Seeking Alpha commentary
• Negative Sentiment: Q1 results missed estimates, with Hims & Hers posting a $0.40 loss per share and $608.1 million in revenue, while gross margin fell as the weight-loss business pivot increased costs and complicated sales recognition. Q1 earnings miss article
• Negative Sentiment: Management also cut profitability expectations for 2026, reinforcing concerns that the GLP-1 transition will pressure near-term earnings even if sales growth accelerates later. Profitability outlook article

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.